西妥昔单抗相关的转移性结直肠癌患者阴囊溃疡 - Suppr

Suppr

超能文献

Cetuximab associated scrotal ulcers in the setting of metastatic colorectal cancer.

作者信息

Arora Neha, Amin Sanober

机构信息

Texas A&M University School of Medicine, Dallas, Texas.

Dermatology Solutions, Grapevine, Texas.

出版信息

JAAD Case Rep. 2024 Aug 30;52:120-121. doi: 10.1016/j.jdcr.2024.08.001. eCollection 2024 Oct.

DOI:10.1016/j.jdcr.2024.08.001

PMID:39385803

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11461954/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e11b/11461954/7e1d599fb38a/gr1.jpg

相似文献

Cetuximab associated scrotal ulcers in the setting of metastatic colorectal cancer.西妥昔单抗相关的转移性结直肠癌患者阴囊溃疡

JAAD Case Rep. 2024 Aug 30;52:120-121. doi: 10.1016/j.jdcr.2024.08.001. eCollection 2024 Oct.

Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial.卡培他滨联合西妥昔单抗维持治疗 RAS 野生型转移性结直肠癌的疗效：一项 2 期临床试验。

JAMA Netw Open. 2020 Jul 1;3(7):e2011036. doi: 10.1001/jamanetworkopen.2020.11036.

Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.磷酸克林霉素和过氧化苯甲酰治疗转移性结直肠癌患者西妥昔单抗相关痤疮样皮疹的疗效、耐受性及对生活质量的影响

J Dermatolog Treat. 2016;27(2):148-52. doi: 10.3109/09546634.2015.1086478. Epub 2015 Sep 24.

[Efficacy of cetuximab in therapy of metastatic colorectal cancer: a system evaluation].西妥昔单抗治疗转移性结直肠癌的疗效：一项系统评价

Zhonghua Yi Xue Za Zhi. 2009 May 26;89(20):1387-90.

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.FOLFOX或每两周一次的XELOX与爱必妥（西妥昔单抗）联合用于野生型KRAS/BRAF转移性结直肠癌患者一线治疗的多中心II期研究：FLEET研究

BMC Cancer. 2015 Oct 14;15:695. doi: 10.1186/s12885-015-1685-z.

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.转移性结直肠癌的进展：西妥昔单抗作用不断增强，优化临床结局。

Clin Transl Oncol. 2010 Aug;12(8):533-42. doi: 10.1007/s12094-010-0551-3.

KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.晚期结直肠癌抗表皮生长因子受体治疗的KRAS检测：基于证据的经济分析

Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1.

Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer.评估双联疗法在转移性 BRAF 突变型结直肠癌中的成本效益。

JAMA Netw Open. 2021 Jan 4;4(1):e2033441. doi: 10.1001/jamanetworkopen.2020.33441.

Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.用于治疗转移性结直肠癌的表皮生长因子受体单克隆抗体

Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742.

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.ICECREAM：西妥昔单抗单药或联合伊立替康用于KRAS、NRAS、BRAF和PI3KCA野生型或G13D突变型转移性结直肠癌患者的随机II期研究。

BMC Cancer. 2016 May 31;16:339. doi: 10.1186/s12885-016-2389-8.

本文引用的文献

A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES.用于治疗各类疾病的单克隆抗体简述

World J Pharm Pharm Sci. 2021 Nov;10(11):14-22.

Prospective practice survey of management of cetuximab-related skin reactions.前瞻性实践调查 Cetuximab 相关皮肤反应的管理。

Support Care Cancer. 2021 Jul;29(7):3497-3506. doi: 10.1007/s00520-020-05862-7. Epub 2020 Nov 4.

Dermatological side effects of targeted antineoplastic therapies: a prospective study.靶向抗肿瘤治疗的皮肤不良反应：一项前瞻性研究。

Cutan Ocul Toxicol. 2020 Dec;39(4):380-384. doi: 10.1080/15569527.2020.1833028. Epub 2020 Oct 20.

Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy.全身性抗肿瘤治疗的皮肤不良反应：细胞毒性化疗、靶向治疗和免疫治疗。

Am Soc Clin Oncol Educ Book. 2020 May;40:485-500. doi: 10.1200/EDBK_289911.

Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.表皮生长因子受体抑制剂西妥昔单抗的不良反应

Acta Dermatovenerol Croat. 2016 Apr;24(1):70-2.

Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents.分子靶向抗癌药物引起的皮肤不良事件的经济负担。

Arch Dermatol. 2011 Dec;147(12):1403-9. doi: 10.1001/archdermatol.2011.719.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验